Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

expression of mTOR conduction pathway in human osteosarcoma MG-63 cells and their stem cells, and the inhibitory effect of different doses of rapamycin

Hao Wu¹, Xuelei Wang², Zhilin Cao¹, Mingdi Zheng¹, Zhongyuan Zhao¹, Yuchi Zhao¹, Jianzhong Zhang³, Gong Cheng¹

¹Department of Orthopedics, Yantaishan Hospital, Yantai, China; ²Department of Orthopedics, Zhaoyuan People's Hospital, Zhaoyuan, China; ³Department of Anesthesiology, Yantaishan Hospital, Yantai, China.

For correspondence:- Gong Cheng Email: doctorchenggong@163.com Tel:+8618553536277

Accepted: 24 March 2022 Published: 30 April 2022

Citation: Wu H, Wang X, Cao Z, Zheng M, Zhao Z, Zhao Y, et al. expression of mTOR conduction pathway in human osteosarcoma MG-63 cells and their stem cells, and the inhibitory effect of different doses of rapamycin. Trop J Pharm Res 2022; 21(4):715-720 doi: 10.4314/tjpr.v21i4.5

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the expressions of rapamycin target protein (mTOR) conduction pathway in human osteosarcoma MG-63 cells and their stem cells, and to examine the inhibitory effect of different doses of rapamycin.

Methods: mTOR mRNA in osteosarcoma stem-like cells and human osteosarcoma MG-63 cells were determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The cells were treated with different doses of rapamycin and divided into low dose group (0.5 mg), medium dose group (1.0 mg), high dose group (2.0 mg) and blank (control) group. Apoptosis and cell cycle of MG-63 cells were determined by flow cytometry, while proliferation of MG-63 cells up was assessed by CCK-8 kit.

Results: mTOR in human osteosarcoma MG-63 cells was significantly lower than that in osteosarcoma stem-like cells. Compared with the control group, mRNA expression levels of mTOR in MG-63 cells and osteosarcoma stem-like cells were significantly decreased after treatment with different concentrations of rapamycin (p < 0.05). MG-63 cells treated with various doses of rapamycin exhibited a significant decrease in their proliferation, compared with control group, while only the high rapamycin concentration group exhibited a significant decrease in osteosarcoma stem-like cell proliferation (p < 0.05). Treatment with rapamycin in MG-63 cells and osteosarcoma stem-like cells resulted in a significant increase in apoptosis, prolonged G0/G1 phase and shortened S phase (p < 0.05).

Conclusion: Rapamycin inhibits the expression of mTOR mRNA in osteosarcoma stem-like and MG-63 cells. It also inhibits the proliferation and cell cycle formation of osteosarcoma stem-like cells and MG-63 cells via mTOR signal pathway. These findings may provide a new target for the treatment of osteosarcoma.

Keywords: Rapamycin, MTOR signal pathway, Human osteosarcoma MG-63, Osteosarcoma stem like cells